| Literature DB >> 26908990 |
Abstract
Nuclear medicine is a rapidly growing discipline that employs advanced novel hybrid techniques that provide unique anatomical and functional information, as well as targets for molecular therapy. Concomitantly, there has been an increase in the attention paid to medical radiation exposure. A radiological justification for the practice of nuclear medicine has been implemented mainly through referral guidelines based on research results such as prospective randomized clinical trials. The International Commission on Radiological Protection recommends diagnostic reference levels as a practical mechanism to optimize medical radiation exposure in order to be commensurate with the medical purpose. The Korean Society of Nuclear Medicine has been implementing radiological optimization through a survey of the protocols on how each hospital determines the dose of administration of each radiopharmaceutical. In the case of nuclear medicine, radiation exposure of caregivers and comforters of patients discharged after administration of therapeutic radiopharmaceuticals can occur; therefore, optimization has been implemented through written instructions for patients, based on international recommendations. The development of patient-radiation-dose monitoring software, and a national registry and management system of patient-radiation-dose is needed to implement radiological optimization through diagnostic reference levels. This management system must work in agreement with the "Institute for Quality Management of Nuclear Medicine", and must take into account the medical reality of Korea, such as low medicine fee, in order to implement reasonable radiological justification and optimization.Entities:
Keywords: Justification; Medical Radiation Exposure; Nuclear Medicine; Optimization
Mesh:
Substances:
Year: 2016 PMID: 26908990 PMCID: PMC4756344 DOI: 10.3346/jkms.2016.31.S1.S59
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Fig. 1Annual number of diagnostic nuclear medicine examinations using gamma camera in Korea.
Diagnostic nuclear medicine examinations using gamma camera in 2013 done in Korea
| System | No. (%) |
|---|---|
| Gastrointestinal | 27,591 (4.92) |
| Thyroid | 93,084 (16.59) |
| Neurological | 21,311 (3.80) |
| Musculoskeletal | 281,815 (50.24) |
| Urological | 38,908 (6.94) |
| Cardiovascular | 81,179 (14.47) |
| Others | 17,105 (3.05) |
| Total | 560,993 (100) |
Diagnostic nuclear medicine examinations using SPECT/CT in 2013 done in Korea
| Examination | No. (%) |
|---|---|
| Hemangioma SPECT/CT (RBC) | 30 (0.39) |
| I-131 SPECT/CT | 1,459 (18.91) |
| I-123 SPECT/CT | 53 (0.69) |
| Parathyroid SPECT/CT (Tc-99m MIBI) | 288 (3.73) |
| Bone SPECT/CT | 5,128 (66.45) |
| WBC SPECT/CT (HMPAO) | 40 (0.52) |
| Ga-67 SPECT/CT | 83 (1.08) |
| Lung perfusion SPECT/CT | 277 (3.59) |
| Sentinel lymphangiography SPECT/CT | 186 (2.41) |
| I-123 MIBG Tumor SPECT/CT | 154 (2.00) |
| Tc-99m MIBI Tumor SPECT/CT | 6 (0.08) |
| In-111 Octreotide Tumor SPECT/CT | 13 (0.17) |
| Total | 7,717 (100) |
Ga-67, gallium 67; MIBI, methoxyisobutylisonitrile; MIBG, metaiodobenzylguanidine; WBC, white blood cell; SPECT/CT, single-photon emission computed tomography/computed tomography; HMPAO, hexamethylpropyleneamineoxime.
Fig. 2Annual number of diagnostic nuclear medicine examinations using PET(/CT) in Korea.
Diagnostic nuclear medicine examinations using PET(/CT) in 2013 done in Korea
| Examination | No. (%) |
|---|---|
| Brain PET(/CT) | 13,149 (3.14) |
| Cardiac PET(/CT) | 118 (0.03) |
| Torso PET(/CT) | 382,882 (91.32) |
| Whole body PET(/CT) | 8,552 (2.04) |
| PET/MR | 2,687 (0.64) |
| F-18 FLT PET | 7 (0.00) |
| F-18 FPCIT PET | 5,818 (1.39) |
| F-18 fluoride PET | 84 (0.02) |
| C-11 acetate PET | 17 (0.00) |
| C-11 Methionine | 453 (0.11) |
| C-11 PIB PET | 66 (0.02) |
| N-13 NH3 | 216 (0.05) |
| Others | 5,226 (1.25) |
| Total | 419,275 (100) |
FLT, fluorothymidine; FPCIT, fluorinated N-3-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane; N-13 NH3, nitrogen-13 ammonia; PIB, Pittsburgh compound B.
Fig. 3Annual number of radiopharmaceutical therapies performed in Korea.
Radiopharmaceutical therapies performed in 2013 in Korea
| Therapy | No. (%) |
|---|---|
| I-131 therapy (outpatient) | 14,235 (43.44) |
| I-131 therapy (inpatient) | 16,286 (46.69) |
| Sr-89 therapy | 22 (0.07) |
| I-131 MIBG therapy | 103 (0.31) |
| SIR-Spheres® Y-90 resin microspheres | 93 (0.28) |
| Y-90 Zevalin® (ibritumomab tiuxetan) | 2 (0.01) |
| Other | 18 (0.05) |
| Total | 32,772 (100) |
MIBG, metaiodobenzylguanidine.
The ICRP recommendations on radiological justification and optimization in medicine
| Justification | Optimization | |
|---|---|---|
| Principal aim | to do more good than harm to the patient | to keep radiation exposure as low as reasonably possible (without deteriorating diagnostic performance) |
| Practical method | referral criteria and patient categorizing in advance | diagnostic reference level* (in case of nuclear medicine administered radiopharmaceuticals dose) |
| Responsibility | In generic justification of a given radiological procedure | The diagnostic reference level values should be selected by professional medical bodies in conjunction with national health and radiological protection authorities. |
*In practice, the values are selected on the basis of a percentile point on the observed distribution of doses to patients or to a reference patient.
Referral guidelines for implementation of radiological justification in nuclear medicine
| Professional bodies | Guidelines |
|---|---|
| International professional bodies | SNMMI; evidence-based referral guidelines |
| Oncology Practice Guidelines Summary from multiple organizations for major cancer Types ( | |
| Cardiac Practice Guidelines Summary ( | |
| ACR; evidence-based rating referral guidelines to assist in making the most appropriate imaging for a specific clinical condition | |
| ACR's Appropriateness Criteria® ( | |
| ATA; evidence-based rating referral guideline through collaboration with related academic societies | |
| Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer (2009) ( | |
| Korean professional bodies | KSNM; evidence-based rating referral guidelines |
| Clinical application of 18F-FDG PET in various cancer ( | |
| Clinical application of 18F-FDG PET in Neurology ( | |
| KTA; evidence-based rating referral guidelines through collaboration with related academic societies | |
| Revised Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer ( |
SNMMI, Society of Nuclear Medicine and Molecular Imaging; ACR, American College of Radiology; ATA, American Thyroid Association; KSNM, Korean Society of Nuclear Medicine; KTA, Korean Thyroid Association.
Numbers in parenthesis are reference numbers.
Guidelines for radiopharmaceuticals dose optimization in nuclear medicine
| Professional bodies | Guidelines |
|---|---|
| International professional bodies | ACR-AAPM; guideline presents diagnostic reference levels |
| ACR-AAPM Practice Parameter for Reference Levels and Achievable Administered Activity for Nuclear Medicine and Molecular Imaging ( | |
| cf) Reference Levels is based on NCRP partial national survey data. | |
| SNMMI; Procedure Standards containing dose recommendations, equipment QC, personnel qualification ( | |
| SNMMI-EANM; harmonized pediatric dose guideline | |
| Pediatric radiopharmaceutical administration: harmonization of the 2007 EANM pediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines ( | |
| IAC Nuclear/PET; standard for PET accreditation | |
| The IAC Standards and Guidelines for Nuclear/PET Accreditation ( | |
| Korean professional bodies | Regarding DRLs; survey is under progress |
| KSNM starts surveying Individual hospital protocols for calculation of administered doses through the KSNM website. | |
| KSNM is developing a survey method for CT Dose Index (CTDI) and Dose Length Products (DLP) | |
| KSNM; procedure guidelines including dose recommendations | |
| Nuclear Medicine Procedure Manual ( | |
| 18F-FDG PET Procedure Standard ( | |
| KSNM; technical standard for radiopharmaceuticals related personnel and facilities | |
| KSNM technical standard for procedures using radiopharmaceuticals ( | |
| Regarding accreditation; relevant foundation is under progress | |
| KARA and other agencies have been performing certification services | |
| A foundation tentatively named the "Institute for Quality Management of Nuclear Medicine," is being established |
ACR, American College of Radiology; AAPM, American Association of Physicists in Medicine; NCRP, National Council on Radiation Protection and Measurements; SNMMI, Society of Nuclear Medicine and Molecular Imaging; EANM, European Association of Nuclear Medicine; KSNM, Korean Society of Nuclear Medicine; KTA, Korean Thyroid Association.
Numbers in parenthesis are reference numbers.
Guidelines for implementation of protection for caregivers and comforters of patients treated with radionuclide
| Organization | Guidelines |
|---|---|
| ICRP | The 2007 Recommendation; dose constraint for caregivers and comforters |
| 5 mSv per episode | |
| 1 mSv for young children, infants, and visitors | |
| International professional bodies | IAEA; Patient instruction card containing restriction periods determined by each hospital |
| ATA; guideline presents restricted periods according to the administered activities | |
| Korean professional bodies | Radiation Safety Guideline for I-131 Thyroid cancer therapy ( |
| MRSRC; radiation safety instruction for I-131 Thyroid cancer therapy presents restricted periods according to the administered activities | |
| Radiation Safety Instruction for I-131 Thyroid cancer therapy ( |
ICRP, International Commission on Radiological Protection; IAEA, International Atomic Energy Agency; ATA, American Thyroid Association; MRSRC, Medical Radiation Safety Research Center
Numbers in parenthesis are reference numbers.